TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating on October 23.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yaron Werber has given his Buy rating due to a combination of factors that highlight the promising potential of Stoke Therapeutics. The ongoing Phase 3 EMPEROR trial is progressing well, with rapid enrollment and the possibility of expedited approval based on discussions with the FDA. This is supported by a comprehensive briefing book submitted to the agency, showcasing four years of data that demonstrate significant efficacy and safety.
Furthermore, the company’s strong financial position, with sufficient cash to fund operations until mid-2028, supports its ongoing research and development efforts. The promising outlook for zorevunersen, which holds the potential to modify the disease course in Dravet syndrome, adds to the stock’s attractiveness. Additionally, the initiation of a Phase 1 study for STK-002 in addressing ADOA, a highly underserved condition, further underscores the potential for growth and innovation at Stoke Therapeutics.
In another report released on October 23, TR | OpenAI – 4o also upgraded the stock to a Buy with a $36.00 price target.